INMB
INmune Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$33.76M
P/E Ratio
—
EPS
$-1.94
Beta
0.89
52W High
$8.67
52W Low
$1.09
50-Day MA
$1.37
200-Day MA
$2.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About INmune Bio Inc
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | 50,000 |
| Gross Profit (TTM) | 50,000 |
| EBITDA | $-30.79M |
| Operating Margin | -61738.00% |
| Return on Equity | -165.20% |
| Return on Assets | -53.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.89 |
| Price-to-Book | 1.37 |
| Price-to-Sales (TTM) | 675.27 |
| EV/Revenue | 169.02 |
| EV/EBITDA | -5.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 257.10% |
| Shares Outstanding | $26.59M |
| Float | $20.61M |
| % Insiders | 17.01% |
| % Institutions | 18.20% |
Analyst Ratings
Consensus ($7.00 target)
1
Strong Buy3
BuyData last updated: 4/8/2026